Professor Anthony Howell 

2006

• The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar, A, Howell, A-, Cuzick, J, Wale, C, Distler, W, Hoctin-Boes, G, Houghton, J, Locker, G, Nabholtz, J. (2006). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol, 7( 8), 633-43. Full text doi:10.1016/S1470-2045(06)70767-7 further details

2005

• Harvie M, Howell A-, Vierkant R, Kumar N, Cerhan J, Kelemen L, Folsom A, Sellers T. (2005). Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev, 14( 3), 656-61. Full text doi:10.1158/1055-9965.EPI-04-0001 further details
• Howell A-, Pippen J, Elledge R, Mauriac L, Vergote I, Jones S, Come S, Osborne C, Robertson J. (2005). Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer, 104( 2), 236-9. Full text doi:10.1002/cncr.21163 further details
• Howell, A-, Cuzick, J, Baum, M, Buzdar, A, Dowsett, M, Forbes, J, Hoctin-Boes, G, Houghton, J, Locker, G, Tobias, J, ATAC Trialists' Group. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365( 9453), 60-2. Full text doi:10.1016/S0140-6736(04)17666-6 further details